{"title_page": "COVID-19 vaccine", "text_new": "<noinclude>{{User:RMCD bot/subject notice|1=COVID-19 vaccine development|2=Talk:COVID-19 vaccine#Requested move 13 April 2020 }}\n</noinclude>{{pp-protected|reason=Persistent [[WP:Disruptive editing|disruptive editing]]; novice editors who can not discern the difference between drugs and vaccines adding incorrect material here.|small=yes}}\n{{short description|Hypothetical vaccine against COVID-19}}\n{{For|COVID-19 drug development|COVID-19 drug development}}\n{{Use dmy dates|date=March 2020}}\n{{2019\u201320 coronavirus pandemic sidebar}}\nA '''COVID-19 vaccine''' is a hypothetical [[vaccine]] against [[coronavirus disease 2019]] (COVID-19). Although no vaccine has completed [[clinical trial]]s, there are multiple attempts in progress to develop such a vaccine.  In late February 2020, the [[World Health Organization]] (WHO) said it did not expect a vaccine against [[SARS-CoV-2]], the causative virus, to become available in less than 18 months.<ref>{{cite web|url=https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away|title=Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus|last1=Grenfell|first1=Rob|last2=Drew|first2=Trevor|date=17 February 2020|website=ScienceAlert|url-status=live|archive-url=https://web.archive.org/web/20200228010631/https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away|archive-date=28 February 2020|access-date=26 February 2020}}</ref> The [[Coalition for Epidemic Preparedness Innovations]] (CEPI) &ndash; which is organizing a {{USD|2 billion}} worldwide fund for rapid investment and development of vaccine candidates<ref name=\"cepi-fund\">{{cite web |title=CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19 |url=https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/ |publisher=Coalition for Epidemic Preparedness Innovations, Oslo, Norway |access-date=23 March 2020 |date=6 March 2020}}</ref> &ndash; indicated in April that a vaccine may be available under emergency use protocols by early 2021.<ref name=\"thanh\">{{cite journal | last=Thanh Le | first=Tung | last2=Andreadakis | first2=Zacharias | last3=Kumar | first3=Arun | last4=G\u00f3mez Rom\u00e1n | first4=Ra\u00fal | last5=Tollefsen | first5=Stig | last6=Saville | first6=Melanie | last7=Mayhew | first7=Stephen | title=The COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery | date=9 April 2020 | issn=1474-1776 | doi=10.1038/d41573-020-00073-5|url=https://www.nature.com/articles/d41573-020-00073-5}}</ref>\n\nBy April 2020, 115 vaccine candidates were in development,<ref name=thanh/><ref name=\"milken\">{{cite web |title=COVID-19 treatment and vaccine tracker |url=https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-9-20-2.pdf |publisher=Milken Institute |access-date=9 April 2020 |date=9 April 2020 |lay-url=https://milkeninstitute.org/covid-19-tracker }}</ref> with two organizations having initiated [[Phases of clinical research#Phase II|Phase I-II safety and efficacy studies in human subjects]].<ref name=\"liu\">{{Cite web|date=10 April 2020|author=Angus Liu|url=https://www.fiercepharma.com/vaccines/china-s-cansino-bio-advances-covid-19-vaccine-into-phase-2-preliminary-safety-data|title=China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data|website=FiercePharma|language=en|access-date=2020-04-13}}</ref><ref name=\"tsn-oxford\">{{Cite web|date=31 March 2020|url=https://www.trialsitenews.com/university-of-oxford-commences-clinical-trial-for-vaccine-candidate-chadox1-ncov-19-targeting-covid-19-2/|title=University of Oxford commences clinical trial for vaccine candidate (ChAdOx1 nCoV-19) Targeting COVID-19|website=Trial Site News|language=en-US|access-date=13 April 2020}}</ref> Five vaccine candidates were in Phase I safety studies in April.<ref name=thanh/>\n\n==Previous coronavirus vaccine projects==\nVaccines have been produced against several diseases caused by coronaviruses for animal use, including for [[infectious bronchitis virus]] in birds, [[canine coronavirus]] and [[feline coronavirus]].<ref>{{cite journal | vauthors = Cavanagh D | title = Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus | journal = Avian Pathology | volume = 32 | issue = 6 | pages = 567\u201382 | date = December 2003 | pmid = 14676007 | doi = 10.1080/03079450310001621198 | doi-access = free }}</ref>\n\nPrevious projects to develop vaccines for viruses in the family ''[[Coronaviridae]]'' that affect humans have been aimed at [[severe acute respiratory syndrome coronavirus]] (SARS) and [[Middle East respiratory syndrome]] (MERS). Vaccines against SARS<ref>{{cite journal | vauthors = Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A | display-authors = 6 | title = Effects of a SARS-associated coronavirus vaccine in monkeys | journal = Lancet | volume = 362 | issue = 9399 | pages = 1895\u20136 | date = December 2003 | pmid = 14667748 | pmc = 7112457 | doi = 10.1016/S0140-6736(03)14962-8 }}</ref> and MERS<ref>{{cite journal | vauthors = Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A | display-authors = 6 | title = Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice | journal = Vaccine | volume = 32 | issue = 45 | pages = 5975\u201382 | date = October 2014 | pmid = 25192975 | pmc = 7115510 | doi = 10.1016/j.vaccine.2014.08.058 }}</ref> have been tested in non-human [[Model organism|animal models]]. As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.<ref name=\"JiangFutureVirology\">{{cite journal | vauthors = Jiang S, Lu L, Du L | title = Development of SARS vaccines and therapeutics is still needed | journal = Future Virology | volume = 8 | issue = 1 | pages = 1\u20132 | date = January 2013 | pmid = 32201503 | pmc = 7079997 | doi = 10.2217/fvl.12.126 }}</ref><ref>{{cite web|url=https://www.nhs.uk/conditions/sars/|title=SARS (severe acute respiratory syndrome)|date=5 March 2020|publisher=[[National Health Service]]|url-status=live|archive-url=https://web.archive.org/web/20200309174230/https://www.nhs.uk/conditions/sars/|archive-date=9 March 2020|access-date=31 January 2020}}</ref> According to [[Academic journal|research paper]]s published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and [[List of national public health agencies|public health agencies]] around the world.<ref name=\"PMID 15655773\">{{cite journal | vauthors = Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM | display-authors = 6 | title = Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice | journal = The Journal of Infectious Diseases | volume = 191 | issue = 4 | pages = 507\u201314 | date = February 2005 | pmid = 15655773 | pmc = 7110081 | doi = 10.1086/427242 }}</ref><ref name=\"PMID 15885812\">{{cite journal | vauthors = Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ | display-authors = 6 | title = Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins | journal = Journal of Virological Methods | volume = 128 | issue = 1\u20132 | pages = 21\u20138 | date = September 2005 | pmid = 15885812 | pmc = 7112802 | doi = 10.1016/j.jviromet.2005.03.021 }}</ref><ref name=\"PMID 16453264\">{{cite journal | vauthors = Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM | display-authors = 6 | title = Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters | journal = The Journal of Infectious Diseases | volume = 193 | issue = 5 | pages = 685\u201392 | date = March 2006 | pmid = 16453264 | pmc = 7109703 | doi = 10.1086/500143 }}</ref>\n\nThere is also no proven vaccine against MERS.<ref>{{cite journal |last1=Shehata |first1=Mahmoud M. |last2=Gomaa |first2=Mokhtar R. |last3=Ali |first3=Mohamed A. |last4=Kayali |first4=Ghazi |title=Middle East respiratory syndrome coronavirus: a comprehensive review |journal=Frontiers of Medicine |date=20 January 2016 |volume=10 |issue=2 |pages=120\u2013136 |doi=10.1007/s11684-016-0430-6 |pmid=26791756 |pmc=7089261 }}</ref> When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.<ref name=\"JiangFutureVirology\" /><ref name=\"Butler3oct2013\">{{cite journal | vauthors = Butler D | title = SARS veterans tackle coronavirus | journal = Nature | volume = 490 | issue = 7418 | pages = 20 | date = October 2012 | pmid = 23038444 | doi = 10.1038/490020a | bibcode = 2012Natur.490...20B | doi-access = free }}</ref> As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans,<ref>{{cite journal | vauthors = Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN | display-authors = 6 | title = Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial | journal = The Lancet. Infectious Diseases | volume = 19 | issue = 9 | pages = 1013\u20131022 | date = September 2019 | pmid = 31351922 | doi = 10.1016/S1473-3099(19)30266-X | doi-access = free }}</ref> and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS,  BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).<ref>{{cite journal | vauthors = Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS | title = Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus | journal = Frontiers in Microbiology | volume = 10 | pages = 1781 | year = 2019 | pmid = 31428074 | pmc = 6688523 | doi = 10.3389/fmicb.2019.01781 }}</ref>\n\n==2020 projects==\n[[COVID-19]] was identified in December 2019.<ref name=\"Fauci\">{{cite journal | vauthors = Fauci AS, Lane HC, Redfield RR | title = Covid-19 - Navigating the Uncharted | journal = The New England Journal of Medicine | volume = 382 | issue = 13 | pages = 1268\u20131269 | date = March 2020 | pmid = 32109011 | doi = 10.1056/nejme2002387 | pmc = 7121221 }}</ref> A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.<ref name=Fauci/><ref name=\"Gates\">{{cite journal | vauthors = Gates B | title = Responding to Covid-19 - A Once-in-a-Century Pandemic? | journal = The New England Journal of Medicine | date = February 2020 | pmid = 32109012 | doi = 10.1056/nejmp2003762 | doi-access = free }}</ref> Many organizations are using published genomes to develop possible [[vaccine]]s against SARS-CoV-2.<ref name=Fauci/><ref name=\"Reut_NIH_Moderna_3months\">{{cite news | last1= Steenhuysen | first1= Julie | last2= Kelland | first2= Kate | name-list-format = vanc | title= With Wuhan virus genetic code in hand, scientists begin work on a vaccine | date= 24 January 2020 | agency= [[Reuters]] | url= https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |access-date=25 January 2020 |archive-url= https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |archive-date= 25 January 2020 |url-status=live }}</ref><ref name=\"clinicaltrialsarena\">{{cite web| first = Praveen | last = Duddu | name-list-format = vanc |url=https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/|title=Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19|publisher=Clinical Trials Arena|date=19 February 2020|access-date=19 February 2020}}</ref><ref name=\"lee\">{{cite news|last=Lee|first=Jaimy| name-list-format = vanc |url=https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06|title=These nine companies are working on coronavirus treatments or vaccines \u2014 here's where things stand|date=1 April 2020|work=[[MarketWatch]]|access-date=2 April 2020|url-status=live}}</ref> In the United States, the [[Food and Drug Administration]] announced its intent \"to use all of the regulatory flexibility granted to it by Congress to ensure the most efficient and timely development of vaccines to fight COVID-19.\"<ref>{{cite press release|url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments|title=Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments|publisher=U.S. [[Food and Drug Administration]] (FDA) |date=19 March 2020|access-date=7 April 2020}}</ref>\n\nSome 79 companies and academic institutions are involved in vaccine development,<ref name=milken/><ref name=thanh/> with three of them receiving support from CEPI, including projects by the [[biotechnology]] companies [[Moderna]],<ref name=\"Ziady\">{{Cite news|last=Ziady|first=Hanna| name-list-format = vanc |url=https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html|title=Biotech company Moderna says its coronavirus vaccine is ready for first tests|date=26 February 2020|access-date=2 March 2020|url-status=live|archive-url=https://web.archive.org/web/20200228083910/https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html|archive-date=28 February 2020|publisher=[[CNN]]}}</ref> and [[Inovio Pharmaceuticals]], and the [[University of Queensland]].<ref name=\"Guardian_CEPI_16weeks\" /> Five hundred clinical studies worldwide, across all stages of development on vaccine and therapeutic candidates for COVID-19, are registered with the World Health Organization Clinical Trial Registry, as of March 2020.<ref name=\"cheng\">{{cite journal |last1=Cheng |first1=Matthew P. |last2=Lee |first2=Todd C. Lee |last3=Tan |first3=Darrell H.S. |last4=Murthy |first4=Srinivas |title=Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic |journal=Canadian Medical Association Journal |date=26 March 2020 |pages=cmaj.200438 |doi=10.1503/cmaj.200438 |doi-access=free }}</ref>\n\nIn early March 2020, CEPI announced a US$2 billion funding goal in a global partnership between public, private, philanthropic, and civil society organisations to accelerate development of COVID-19 vaccines, with commitments to date by the governments of Denmark, Finland, Germany, Norway, and the UK.<ref name=cepi-fund/> Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.<ref name=thanh/>\n\n===Technology platforms===\nIn April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.<ref name=thanh/> Major platform targets advanced into Phase I safety studies include:\n*[[nucleic acid]] ([[DNA]] and [[RNA]]) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)\n*[[viral vector]] (Phase I developer and vaccine candidate: CanSino Biologics, [[adenovirus]] type 5 vector)\n*virus-like particle involved in [[DNA replication]] (Phase I developer and vaccine candidate: Shenzhen Geno-Immune Medical Institute, LV-SMENP)\n\nAccording to CEPI, the platforms based on DNA or [[messenger RNA]] offer considerable promise to alter COVID-19 [[antigen]] functions for strong immune responses, and can be rapidly assessed, refined for long-term stability, and prepared for large-scale production capacity.<ref name=thanh/> Other platforms being developed in 2020 focus on [[peptide]]s, [[recombinant protein]]s, live [[attenuated virus]]es, and [[Virus_processing#Viral_inactivation|inactivated viruses]].<ref name=thanh/>\n\nIn general, the vaccine technologies being developed for COVID-19 are not like vaccines already in use to prevent influenza, but rather are using \"next-generation\" strategies for precision on the COVID-19 infection mechanisms, while hastening development for eventually preventing infection with a new vaccine.<ref name=thanh/> Vaccine platforms in development are also designed to address mechanisms for infection susceptibility to COVID-19 in specific population subgroups, such as the elderly, children, pregnant women, or people with existing weakened [[immune system]]s.<ref name=thanh/>\n\nCEPI classifies development stages for vaccines as either \"exploratory\" (planning and designing a candidate, with no evaluation [[in vivo]] yet), \"preclinical\" (in vivo evaluation with preparation for manufacturing a compound to test in humans), or [[Phases of clinical research#Phase_I|initiation of Phase I safety studies in healthy people]].<ref name=thanh/>\n\n==Vaccine candidates==\nAs reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute<ref name=milken/>), and 37 others announced, but with little public information available (presumed to be in planning or being designed).<ref name=thanh/> Of the 79 confirmed active projects,<ref name=milken/> 74 are either in \"exploratory\" or \"preclinical\" development, according to the early-April CEPI report.<ref name=thanh/>\n\nIn April after the CEPI report was published, Phase I-II [[Randomized controlled trial|randomized, interventional]] trials for [[Effective dose (pharmacology)|dosing]] and assessment for [[side effect]]s began in [[Wuhan]], China on the candidate vaccine, Ad5-nCoV (CanSino Biologics, table),<ref name=liu/> and in England on the candidate, ChAdOx1 nCoV-19.<ref name=tsn-oxford/> Only five other trials on vaccine candidates are in Phase I human testing, as of mid-April.<ref name=thanh/>\n\nPhase I trials test primarily for safety and preliminary dosing in a few dozen healthy subjects, while Phase II trials &ndash; following success in Phase I &ndash; evaluate [[immunogenicity]], dose levels (efficacy based on [[biomarker]]s) and adverse effects of the candidate vaccine, typically in hundreds of people.<ref name=\"Vaccines.gov\">{{cite web |title=Vaccine Safety - Vaccines |url=https://www.vaccines.gov/basics/safety |website=www.vaccines.gov |publisher=US Department of Health and Human Services |accessdate=13 April 2020}}</ref><ref name=\"fda-ddp\">{{cite web |title=The drug development process |url=https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process |publisher=US Food and Drug Administration |access-date=12 April 2020 |date=4 January 2018}}</ref> A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.<ref name=fda-ddp/> Phase III trials typically involve more participants, including a [[control group]], and test effectiveness of the vaccine to prevent the disease, while monitoring for [[adverse effect]]s at the optimal dose.<ref name=Vaccines.gov/><ref name=fda-ddp/>\n\n===Clinical trials===\n\n{| class=\"wikitable\"\n|-\n! colspan=\"6\" style=\"background-color: #CCEEEE;\" | COVID-19: candidate vaccines in Phase I-II trials\n|-\n! Vaccine candidate \n(developer/sponsor)\n! Technology\n! Phase of trial \n(participants)\n! Location\n! Duration\n! References \nand notes\n|-\n| '''Ad5-nCoV'''\n(CanSino Biologics)\n| recombinant adenovirus type 5 vector\n| Phase II interventional trial for dosing and side effects (500)\n| Wuhan, China\n| March 2020 to December 2020\n| <ref name=liu/><ref name=\"Phase II Ad5-nCov\">{{ClinicalTrialsGov|NCT04341389|A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)}}</ref>\n|-\n| '''Ad5-nCoV'''\n(CanSino Biologics)\n| recombinant adenovirus type 5 vector\n| Phase I (108)\n| Wuhan, China\n| March 2020 to December 2020\n| <ref name=thanh/><ref name=\"CTgov Ad5-nCoV\">{{ClinicalTrialsGov|NCT04313127|A Phase I Clinical Trial in 18-60 Adults}}</ref> <small>continuing through 2020 during Phase II start<ref name=liu/>\n|-\n| '''ChAdOx1 nCoV-19'''\n([[University of Oxford]])\n| adenovirus vector\n| Phase I-II, randomized, placebo-controlled, multiple sites (510)\n| England\n| April 2020 to May 2021\n| <ref name=tsn-oxford/><ref name=\"04324606-oxford\">{{ClinicalTrialsGov|NCT04324606|A Study of a Candidate COVID-19 Vaccine (COV001)}}</ref>\n|-\n| '''mRNA-1273'''\n([[Moderna]], US [[National Institute of Allergy and Infectious Diseases]])\n| [[lipid]] [[nanoparticle]] dispersion containing messenger RNA\n| Phase I (45)\n| United States\n| March 2020 to Spring-Summer 2021\n| <ref name=thanh/><ref name=\"NIH-director-16-March\">{{cite web |title=NIH clinical trial of investigational vaccine for COVID-19 begins |url=https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |publisher=US National Institutes of Health |access-date=17 March 2020 |language=EN |date=16 March 2020}}</ref><ref name=\"mod-04283461\">{{ClinicalTrialsGov|NCT04283461|Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection}}</ref>\n|-\n| '''Covid-19/aAPC'''\n(Shenzhen Geno-Immune Medical Institute)\n| [[Lentiviral vector in gene therapy|lentiviral vector]], pathogen-specific artificial antigen presenting [[dendritic cell]]s \n| Phase I (100)\n| [[Shenzhen]], China\n| March 2020 to 2023\n| <ref name=thanh/><ref name=\"shenz-04299724\">{{ClinicalTrialsGov|NCT04299724|Safety and Immunity of Covid-19 aAPC Vaccine}}</ref>\n|-\n| '''LV-SMENP-DC'''\n(Shenzhen Geno-Immune Medical Institute) \n| lentiviral minigene vaccine, dendritic cells modified with lentiviral vector\n| Phase I (100)\n| Shenzhen, China\n| March 2020 to 2023\n| <ref name=thanh/><ref name=\"shenz-04276896\">{{ClinicalTrialsGov|NCT04276896|Immunity and Safety of Covid-19 Synthetic Minigene Vaccine}}</ref>\n|-\n| '''INO-4800'''\n([[Inovio Pharmaceuticals]], CEPI)\n| DNA [[plasmid]] delivered by [[electroporation]]\n| Phase I (40)\n| United States\n| April 2020 to November 2020\n| <ref name=thanh/><ref name=\"Inov-04336410\">{{ClinicalTrialsGov|NCT04336410|Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers}}</ref>\n|-\n|}\n===Preclinical research===\n{{Prose|section|date=April 2020}}\n\nOf 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in \"preclinical\" research).<ref name=thanh/><ref name=milken/>\n\n*Around 24 January 2020 in Australia, the [[University of Queensland]] announced that it is investigating the potential of a [[molecular clamp]] vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.<ref name=\"Guardian_CEPI_16weeks\">{{cite news|last1=Devlin|first1=Hannah| name-list-format = vanc |url=https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine|title=Lessons from SARS outbreak help in race for coronavirus vaccine|date=24 January 2020|newspaper=[[The Guardian]]|access-date=25 January 2020|url-status=live|archive-url=https://web.archive.org/web/20200125203322/https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine|archive-date=25 January 2020}}</ref>\n*Around 24 January 2020, the [[Vaccine and Infectious Disease Organization|International Vaccine Centre]] (VIDO-InterVac) at the [[University of Saskatchewan]] announced the commencement of work on a vaccine, aiming to start human testing in 2021.<ref name=\"CBC_Saskatch_6_8_weeks_nonhuman\">{{cite news|url=https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118|title=Saskatchewan lab joins global effort to develop coronavirus vaccine|date=24 January 2020|access-date=25 January 2020|url-status=live|archive-url=http://archive.today/jYfcU|archive-date=25 January 2020|publisher=[[CBC News]]|agency=[[The Canadian Press]]}}</ref>\n* Vaccine development projects were announced at the [[Chinese Center for Disease Control and Prevention]],<ref>{{cite news|last=Jeong-ho|first=Lee |last2=Zheng|first2=William|last3=Zhou|first3=Laura | name-list-format = vanc |url= https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |title=Chinese scientists race to develop vaccine as coronavirus death toll jumps|date=26 January 2020|work=[[South China Morning Post]]|access-date=28 January 2020 |url-status=live |archive-url= https://web.archive.org/web/20200126073453/https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |archive-date=26 January 2020 }}</ref> and the [[University of Hong Kong]].<ref name=\"HKvaccine\">{{cite news|last1=Cheung|first1=Elizabeth|url=https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have|title=Hong Kong researchers have developed coronavirus vaccine, expert reveals|date=28 January 2020|work=[[South China Morning Post]]|access-date=28 January 2020|url-status=live|archive-url=https://web.archive.org/web/20200128154002/https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have|archive-date=28 January 2020}}</ref>\n* Around 29 January 2020, [[Janssen Pharmaceutical Companies]], led by [[Hanneke Schuitemaker]], announced that it had begun work on developing a vaccine.<ref>{{Cite news|last=Mishra|first=Manas | name-list-format = vanc |url=https://www.reuters.com/article/us-china-health-johnson-johnson-idUSKBN1ZS1VW|title=Johnson & Johnson working on vaccine for deadly coronavirus|date=29 January 2020|access-date=19 February 2020|url-status=live|archive-url=https://web.archive.org/web/20200129231718/https://www.reuters.com/article/us-china-health-johnson-johnson-idUSKBN1ZS1VW|archive-date=29 January 2020|agency=[[Reuters]]|editor-last=Orr|editor-first=Bernard|editor-last2=Kuber|editor-first2=Shailesh}}</ref> Janssen is co-developing an oral vaccine with its biotechnology partner, [[Vaxart]].<ref name=\"nas\">{{cite web |title=Vaxart (VXRT) - A long shot or perfect shot? |url=https://www.nasdaq.com/articles/vaxart-vxrt-a-long-shot-or-perfect-shot-2020-02-25 |publisher=NASDAQ, RTTNews.com |access-date=1 March 2020 |date=25 February 2020}}</ref> On 18 March 2020, [[Emergent BioSolutions]] announced a manufacturing partnership with Vaxart to develop the vaccine.<ref>{{cite news|first=Sara|last=Gilgore| name-list-format = vanc |url=https://www.bizjournals.com/washington/news/2020/03/18/emergent-biosolutions-dives-into-another.html|title=Emergent BioSolutions dives into another coronavirus vaccine effort|work=Washington Business Journal|date=18 March 2020|access-date=18 March 2020}}</ref>\n*On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of an vaccine-design with a similar technology like the one used for cancer neoantigen vaccination therapy\" against COVID-19.<ref>{{Cite journal|last=Bojin|first=Florina|last2=Gavriliuc|first2=Oana|last3=Margineanu|first3=Michael-Bogdan|last4=Paunescu|first4=Virgil| name-list-format = vanc |date=2020-02-08|title=Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV)|url=https://www.preprints.org/manuscript/202002.0102/v1|language=en}}</ref> On 25 March the head of the research institute announced that they finalized the synthesis of the vaccine and that they were beginning the tests.<ref>{{Cite web|url=http://www.romania-actualitati.ro/vaccin-impotriva-noului-coronavirus-in-teste-la-oncogen-timisoara-136664|title=\"Vaccin \u00eempotriva noului coronavirus\", \u00een teste la OncoGen Timi\u0219oara - Rom\u00e2nia - Radio Rom\u00e2nia Actualit\u0103\u0163i Online|website=www.romania-actualitati.ro|access-date=2020-03-28}}</ref>\n* On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology announces they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19. They wanted to produce a vaccine candidate that could be tested in humans \"within 90 days.\"<ref>{{cite press release|url=https://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html|title=Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines|date=2020-02-27|access-date=2020-03-25|publisher=Generex}}</ref>\n*[[Washington University in St. Louis]] announced its projects to develop a vaccine on 5 March 2020.<ref>{{cite news |last1=Chen |first1=Eli |title=Wash U Scientists Are Developing A Coronavirus Vaccine |url=https://news.stlpublicradio.org/post/wash-u-scientists-are-developing-coronavirus-vaccine |work=St. Louis Public Radio |date=March 5, 2020 }}</ref>\n* On 5 March 2020, the [[United States Army Medical Research and Materiel Command]] at [[Fort Detrick]] and the [[Walter Reed Army Institute of Research]] in [[Silver Spring, Maryland|Silver Spring]], both in western Maryland, announced they were working on a vaccine.<ref>{{cite web |title=Defense Department Press Briefing Investigating and Developing Vaccine Candidates Against COVID-19 (Transcript) |url=https://www.defense.gov/Newsroom/Transcripts/Transcript/Article/2104736/defense-department-press-briefing-investigating-and-developing-vaccine-candidat/ |publisher=United States Department of Defense |location=Arlington, VA |date=5 March 2020 |access-date=19 March 2020}}</ref>\n* Emergent Biosolutions announced that it had teamed with [[Novavax]] Inc. in the development and manufacture of a vaccine. The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.<ref>{{cite news |last1=Gilgore |first1=Sara | name-list-format = vanc |title=Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions |url=https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html |work=Washington Business Journal |publisher=American City Business Journals |date=10 March 2020 |location=Charlotte, NC}}</ref>\n* On 12 March 2020, India's Health Ministry announced they are working with 11 isolates and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.<ref>{{cite news |title=Will take one-and-a-half to two years for India to develop vaccine for COVID-19: Health Ministry |url=https://economictimes.indiatimes.com/news/politics-and-nation/will-take-one-and-a-half-to-two-years-for-india-to-develop-vaccine-for-covid-19-health-ministry/articleshow/74597044.cms |work=Economic Times|date=12 March 2020 |access-date=12 March 2020}}</ref>\n* On 12 March 2020, Medicago, a biotechnology company in [[Quebec City]], [[Quebec]], reported development of a coronavirus [[virus-like particle]] under partial funding from the [[Canadian Institutes for Health Research]].<ref name=\"can-funding\">{{cite web |title=Government of Canada funds 49 additional COVID-19 research projects \u2013 Details of the funded projects |url=https://www.canada.ca/en/institutes-health-research/news/2020/03/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html |publisher=Government of Canada |access-date=23 March 2020 |date=23 March 2020}}</ref><ref name=\"abedi\">{{cite news | first = Maham | last = Abedi | name-list-format = vanc |title=Canada to spend $192M on developing COVID-19 vaccine |url=https://globalnews.ca/news/6717883/coronavirus-canada-vaccine-spending/ |access-date=24 March 2020 |work=Global News |date=23 March 2020}}</ref><ref name=\"bw3-12\">{{cite news|url=https://www.businesswire.com/news/home/20200312005345/en/|title=Medicago announces production of a viable vaccine candidate for COVID-19|date=2020-03-12|access-date=2020-03-24|work=Business Wire}}</ref> The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.<ref name=abedi/><ref name=bw3-12/>\n* On 16 March 2020, the European Commission offered an [[Euro sign|\u20ac]]80 million investment in [[CureVac]], a German biotechnology company, to develop a [[messenger RNA|mRNA]] vaccine.<ref name=\"curevac\">{{cite web |title=Coronavirus: Commission offers financing to innovative vaccines company CureVac |url=https://ec.europa.eu/commission/presscorner/detail/en/ip_20_474 |publisher=European Commission |access-date=19 March 2020 |date=16 March 2020}}</ref> Earlier that week, ''[[The Guardian]]'' reported that the US President [[Donald Trump]] had offered CureVac \"'large sums of money' for exclusive access to a Covid-19 vaccine\", against which the [[Cabinet of Germany|German government]] protested.<ref>{{cite web|url=https://www.theguardian.com/us-news/2020/mar/15/trump-offers-large-sums-for-exclusive-access-to-coronavirus-vaccine|title=Trump 'offers large sums' for exclusive access to coronavirus vaccine|first=Philip|last=Oltermann| name-list-format = vanc |newspaper=[[The Guardian]]|date=15 March 2020}}</ref>\n* On 17 March 2020, American pharmaceutical company [[Pfizer]] announced a partnership with German company [[:de:BioNTech|BioNTech]] to jointly develop a mRNA-based vaccine.<ref name=\"techcrunch\">{{Cite news |url=https://techcrunch.com/2020/03/17/pfizer-and-biontech-announce-joint-development-of-a-potential-covid-19-vaccine/ |title=Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine |date=18 March 2020 |work=TechCrunch |access-date=18 March 2020}}</ref> mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.<ref>{{Cite web|url=http://www.shelstonip.com/news/covid-19-mrna-vaccines-a-promising-approach-to-vaccine-development/|title=COVID-19: mRNA vaccines \u2013 a promising approach to vaccine development|date=2020-03-23|website=Shelston IP Australia \u2013 Intellectual Property & Patent Services {{!}} IP Attorneys & IP Lawyers|language=en-US|access-date=2020-03-23}}</ref>\n* In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.<ref>{{cite press release |author=<!--Staff writer(s); no by-line.--> |title=Takis, a biotech company in Castel Romano, Rome, announced that it is ready to test its COVID-19 vaccine on pre-clinical models. |url=http://www.takisbiotech.it/images/doc/Covid-19_vaccine_on_pre-clinical_models_eng.pdf |location=Rome |publisher=Takis Biotech |agency= |date=2020-03-17 |access-date=2020-03-24}}</ref>\n* In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the [[Institut Pasteur]], Themis Bioscience ([[Vienna]], [[Austria]]), and the [[University of Pittsburgh]], bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.<ref name=\"cepi3-19\">{{cite web |title=CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine |url=https://cepi.net/news_cepi/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine/ |publisher=Coalition for Epidemic Preparedness Innovations |access-date=23 March 2020 |date=19 March 2020}}</ref> CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the [[University of Hong Kong]], the University of Oxford, and the University of Queensland.<ref name=cepi3-19/>\n* On 20 March 2020, Russian health officials announced that scientists have began animal testing of six different vaccine candidates.<ref>{{cite news |url=https://www.usnews.com/news/world/articles/2020-03-20/russia-starts-testing-coronavirus-vaccine-prototypes-on-animals |title=Russia starts testing coronavirus vaccine prototypes on animals| first = Andrew | last = Osborn | name-list-format = vanc |date=20 March 2020 |work=U.S. News & World Report|agency=Thomson Reuters |access-date=2020-03-21}}</ref>\n* [[Imperial College London]] researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19. The vaccine candidate was developed within 14 days of receiving the sequence from China.<ref>{{cite press release |first=Joanna|last=Wilson | name-list-format = vanc |title=In pictures: the Imperial lab developing a COVID-19 vaccine |url= https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid-19-vaccine/|location=London |publisher=Imperial College London |agency= |date=2020-03-20 |access-date=2020-03-24}}</ref>\n*In late March, the [[Government of Canada|Canadian government]] announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.<ref name=can-funding/><ref name=abedi/><ref name=\"CBC_Saskatch_6_8_weeks_nonhuman\"/><ref name=bw3-12/> Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national \"vaccine bank\" of several new vaccines that could be used if another coronavirus outbreak occurs.<ref name=\"abedi\" />\n*On 2 April 2020, researchers at the [[University of Pittsburgh School of Medicine]] reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that \"MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization.\"<ref name=\"TRIB-2020402\">{{cite news |last=Martines |first=Jamie | name-list-format = vanc |title=Pittsburgh scientists develop possible coronavirus vaccine, hope FDA can fast-track it |url=https://triblive.com/local/pittsburgh-allegheny/pittsburgh-scientists-say-coronavirus-vaccine-could-be-fast-tracked-after-key-animal-testing/ |date=2 April 2020 |work=[[Pittsburgh Tribune-Review]] |access-date=2 April 2020 }}</ref><ref name=\"EBM-20200402\">{{cite journal |last1=Kim |first1=Eun |last2=Erdos |first2=Geza |last3=Huang |first3=Shaohua |last4=Kenniston |first4=Thomas W. |last5=Balmert |first5=Stephen C. |last6=Carey |first6=Cara Donahue |last7=Raj |first7=V. Stalin |last8=Epperly |first8=Michael W. |last9=Klimstra |first9=William B. |last10=Haagmans |first10=Bart L. |last11=Korkmaz |first11=Emrullah |last12=Falo |first12=Louis D. |last13=Gambotto |first13=Andrea |title=Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development |journal=EBioMedicine |date=April 2020 |pages=102743 |doi=10.1016/j.ebiom.2020.102743 |pmid=32249203 |pmc=7128973 |lay-url=https://www.sciencedaily.com/releases/2020/04/200402144508.htm |lay-source=ScienceDaily |lay-date=April 2, 2020 }}</ref>\n\nIn March 2020, the US government, industry, and three universities pooled resources to access [[supercomputer]]s from [[IBM]], combined with [[cloud computing]] resources from [[Hewlett Packard Enterprise]], [[Amazon (company)|Amazon]], [[Microsoft]], and [[Google]].<ref name=\"cnet\">{{Cite web|url=https://www.cnet.com/news/sixteen-supercomputers-tackle-coronavirus-cures-in-us/|title=Sixteen supercomputers tackle coronavirus cures in US|last=Shankland|first=Stephen| name-list-format = vanc |website=CNET|language=en|access-date=2020-03-23}}</ref><ref name=\"covidhpc\">{{cite web|url=https://covid19-hpc.mybluemix.net |title=Homepage of The COVID-19 High Performance Computing Consortium | access-date=2020-03-28}}</ref> The ''COVID-19 High Performance Computing Consortium'' is being used to [[Forecasting|forecast]] disease spread, [[Data modeling|model]] possible vaccines, and [[High-throughput screening|screen]] thousands of chemical compounds to design a COVID-19 vaccine or therapy.<ref name=cnet/><ref name=covidhpc/>\n\nAn additional consortium of Microsoft, six universities (including one in the first consortium), and the [[National Center for Supercomputer Applications]], working under the auspices of C3.ai, a company founded by billionaire software developer [[Thomas Siebel]], are currently pooling their supercomputer resources for the same uses alongside developing medical protocols and strengthening public health strategies around the world, as well as awarding large grants to researchers who propose to use AI to carry out similar tasks by May.<ref>{{cite web|url=https://c3.ai/c3-ai-microsoft-and-leading-universities-launch-c3-ai-digital-transformation-institute/ |title=C3.ai, Microsoft, and Leading Universities Launch C3.ai Digital Transformation Institute |date=2020-03-26 |access-date=2020-03-28}}</ref><ref>{{cite news|last=Broad |first=William | name-list-format = vanc |url=https://www.nytimes.com/2020/03/26/science/ai-versus-the-coronavirus.html |title=A.I. Versus the Coronavirus |website=The New York Times |date=2020-03-26 |access-date=2020-03-28}}</ref>\n\n===Non-specific vaccine===\n\nSome vaccines have [[heterologous effects]], also called non-specific effects. That means they can have benefits beyond the disease they prevent.<ref name=\"Kleinnijenhuis 2015\">{{cite journal |last1=Kleinnijenhuis |first1=J |last2=van Crevel |first2=R |last3=Netea |first3=MG |title=Trained immunity: consequences for the heterologous effects of BCG vaccination. |journal=Transactions of the Royal Society of Tropical Medicine and Hygiene |date=January 2015 |volume=109 |issue=1 |pages=29-35 |doi=10.1093/trstmh/tru168 |pmid=25573107}}</ref> The anti-tuberculosis vaccine, [[BCG vaccine]], is an example that is being tested to determine if it has a protective effect against COVID-19, pursuant to assertions that COVID-19 mortality was lower in countries having routine BCG vaccine administration.<ref name=\"deVrieze-April\">{{cite journal |last1=de Vrieze |first1=Jop |title=Can a century-old TB vaccine steel the immune system against the new coronavirus? |journal=Science |date=March 23, 2020 |doi=10.1126/science.abb8297 |url=https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus |accessdate=11 April 2020}}</ref>\n\nIn March 2020, a randomized trial of BCG vaccine to reduce COVID-19 illness began in the Netherlands, seeking to recruit 1,000 healthcare workers.<ref name=\"BCG-EudraCT\">{{cite web |title=EudraCT 2020-000919-69 |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL |website=EU Clinical Trials Register |publisher=European Union |accessdate=11 April 2020}}</ref> A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.<ref name=\"MCRI-BCG-trial\">{{cite web |title=Murdoch Children\u2019s Research Institute to trial preventative vaccine for COVID-19 healthcare workers |url=https://www.mcri.edu.au/news/murdoch-children%E2%80%99s-research-institute-trial-preventative-vaccine-covid-19-healthcare-workers |website=www.mcri.edu.au |publisher=Murdoch Children's Research Institute |accessdate=11 April 2020 |language=en}}</ref><ref name=\"CT.gov BCG Australia\">{{cite web |title=BCG Vaccination to Protect Healthcare Workers Against COVID-19 - Full Text View - ClinicalTrials.gov |url=https://clinicaltrials.gov/ct2/show/NCT04327206 |website=clinicaltrials.gov |publisher=US National Library of Medicine, National Institutes of Health |accessdate=11 April 2020 |language=en}}</ref>\n\n==Potential limitations==\nIt is possible vaccines in development will not be safe or effective.<ref name=\"Thorp\">{{cite journal |last1=Thorp |first1=H. Holden |title=Underpromise, overdeliver |journal=Science |date=27 March 2020 |volume=367 |issue=6485 |pages=1405 |doi=10.1126/science.abb8492 |pmid=32205459 |doi-access=free }}</ref> One study found that between 2006 and 2015, the success rate of obtaining approval from Phase I to successful Phase III trials was 16.2% for vaccines,<ref name=\"bio\">{{cite web|url=https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf|title=Clinical Development Success Rates 2006-2015|date=June 2016|publisher=BIO Industry Analysis}}</ref> and CEPI indicates a potential success rate of only 10% for vaccine candidates in 2020 development.<ref name=thanh/>\n\nThe rapid development and urgency of producing a vaccine for the COVID-19 pandemic may increase the risks and failure rate of delivering a safe, effective vaccine.<ref name=thanh/> Early research to assess vaccine efficacy using COVID-19-specific animal models, such as [[ACE2]]-[[transgenic]] mice, other laboratory animals, and non-human primates, indicate a need for [[biosafety]]-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.<ref name=thanh/> An April 2020 CEPI report stated: \"strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions.\"<ref name=thanh/>\n\nWhile the [[flu vaccine]] is typically [[Mass production|mass-produced]] by injecting the virus into [[chicken egg]]s, this method will not work for the COVID-19 vaccine, as the SARS-CoV-2 virus cannot replicate inside eggs.<ref>{{Cite web|url=https://www.cnn.com/2020/03/27/health/chicken-egg-flu-vaccine-intl-hnk-scli/index.html|title=Millions of chickens are used to make vaccines each year. But that won't work for coronavirus|last=Yeung|first=Jessie| name-list-format = vanc |date=29 March 2020|website=CNN|url-status=live|archive-url=|archive-date=|access-date=2020-04-04}}</ref>\n\n==Misinformation==\n{{main|Misinformation related to the 2019\u201320 coronavirus pandemic}}\nSocial media posts have promoted a [[conspiracy theory]] claiming the virus behind COVID-19 was known and that a vaccine was already available. The patents cited by various [[social media]] posts reference existing patents for [[genetic sequence]]s and vaccines for other strains of coronavirus such as the [[Severe acute respiratory syndrome-related coronavirus|SARS coronavirus]].<ref>{{Cite web|url=https://www.politifact.com/factchecks/2020/jan/23/facebook-posts/there-outbreak-china-wuhan-coronavirus-there-not-v/|title=No, there is no vaccine for the Wuhan coronavirus|last=Kertscher|first=Tom| name-list-format = vanc |date=23 January 2020|website=[[PolitiFact]]|publisher=[[Poynter Institute]]|url-status=live|archive-url=https://web.archive.org/web/20200207133056/https://www.politifact.com/factchecks/2020/jan/23/facebook-posts/there-outbreak-china-wuhan-coronavirus-there-not-v/|archive-date=7 February 2020|access-date=7 February 2020}}</ref><ref name=\"20200124factcheckA\">{{Cite web|url=https://www.factcheck.org/2020/01/social-media-posts-spread-bogus-coronavirus-conspiracy-theory/|title=Social Media Posts Spread Bogus Coronavirus Conspiracy Theory|last=McDonald|first=Jessica| name-list-format = vanc |date=24 January 2020|website=[[FactCheck.org]]|publisher=[[Annenberg Public Policy Center]]|url-status=live|archive-url=https://web.archive.org/web/20200206102802/https://www.factcheck.org/2020/01/social-media-posts-spread-bogus-coronavirus-conspiracy-theory/|archive-date=6 February 2020|access-date=8 February 2020}}</ref>\n\n== See also ==\n* [[2019\u201320 coronavirus pandemic]]\n* [[Coronavirus disease 2019]]\n* [[Severe acute respiratory syndrome coronavirus 2]]\n* [[2009 flu pandemic vaccine]]\n* [[Respiratory disease]]\n* [[COVID-19 drug development]]\n* [[Phases of clinical research]]\n{{Portal bar|Coronavirus disease 2019|Medicine|Modern history|Viruses|Current events|border=no}}\n\n== References ==\n{{reflist}}\n\n== External links ==\n* {{cite web | url=https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker | title=COVID-19 Vaccine Tracker | website=Regulatory Focus }}\n\n{{2019\u201320 coronavirus pandemic}}\n{{Vaccines}}\n\n[[Category:Vaccines]]\n[[category:COVID-19|Vaccine]]\n[[Category:Medical research]]\n", "text_old": "<noinclude>{{User:RMCD bot/subject notice|1=COVID-19 vaccine development|2=Talk:COVID-19 vaccine#Requested move 13 April 2020 }}\n</noinclude>{{pp-protected|reason=Persistent [[WP:Disruptive editing|disruptive editing]]; novice editors who can not discern the difference between drugs and vaccines adding incorrect material here.|small=yes}}\n{{short description|Hypothetical vaccine against COVID-19}}\n{{For|COVID-19 drug development|COVID-19 drug development}}\n{{Use dmy dates|date=March 2020}}\n{{2019\u201320 coronavirus pandemic sidebar}}\nA '''COVID-19 vaccine''' is a hypothetical [[vaccine]] against [[coronavirus disease 2019]] (COVID-19). Although no vaccine has completed [[clinical trial]]s, there are multiple attempts in progress to develop such a vaccine.  In late February 2020, the [[World Health Organization]] (WHO) said it did not expect a vaccine against [[SARS-CoV-2]], the causative virus, to become available in less than 18 months.<ref>{{cite web|url=https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away|title=Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus|last1=Grenfell|first1=Rob|last2=Drew|first2=Trevor|date=17 February 2020|website=ScienceAlert|url-status=live|archive-url=https://web.archive.org/web/20200228010631/https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away|archive-date=28 February 2020|access-date=26 February 2020}}</ref> The [[Coalition for Epidemic Preparedness Innovations]] (CEPI) &ndash; which is organizing a {{USD|2 billion}} worldwide fund for rapid investment and development of vaccine candidates<ref name=\"cepi-fund\">{{cite web |title=CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19 |url=https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/ |publisher=Coalition for Epidemic Preparedness Innovations, Oslo, Norway |access-date=23 March 2020 |date=6 March 2020}}</ref> &ndash; indicated in April that a vaccine may be available under emergency use protocols by early 2021.<ref name=\"thanh\">{{cite journal | last=Thanh Le | first=Tung | last2=Andreadakis | first2=Zacharias | last3=Kumar | first3=Arun | last4=G\u00f3mez Rom\u00e1n | first4=Ra\u00fal | last5=Tollefsen | first5=Stig | last6=Saville | first6=Melanie | last7=Mayhew | first7=Stephen | title=The COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery | date=9 April 2020 | issn=1474-1776 | doi=10.1038/d41573-020-00073-5|url=https://www.nature.com/articles/d41573-020-00073-5}}</ref>\n\nBy April 2020, 115 vaccine candidates were in development,<ref name=thanh/><ref name=\"milken\">{{cite web |title=COVID-19 treatment and vaccine tracker |url=https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-9-20-2.pdf |publisher=Milken Institute |access-date=9 April 2020 |date=9 April 2020 |lay-url=https://milkeninstitute.org/covid-19-tracker }}</ref> with two organizations having initiated [[Phases of clinical research#Phase II|Phase I-II safety and efficacy studies in human subjects]].<ref name=\"liu\">{{Cite web|date=10 April 2020|author=Angus Liu|url=https://www.fiercepharma.com/vaccines/china-s-cansino-bio-advances-covid-19-vaccine-into-phase-2-preliminary-safety-data|title=China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data|website=FiercePharma|language=en|access-date=2020-04-13}}</ref><ref name=\"tsn-oxford\">{{Cite web|date=31 March 2020|url=https://www.trialsitenews.com/university-of-oxford-commences-clinical-trial-for-vaccine-candidate-chadox1-ncov-19-targeting-covid-19-2/|title=University of Oxford commences clinical trial for vaccine candidate (ChAdOx1 nCoV-19) Targeting COVID-19|website=Trial Site News|language=en-US|access-date=13 April 2020}}</ref> Five vaccine candidates were in Phase I safety studies in April.<ref name=thanh/>\n\n==Previous coronavirus vaccine projects==\nVaccines have been produced against several diseases caused by coronaviruses for animal use, including for [[infectious bronchitis virus]] in birds, [[canine coronavirus]] and [[feline coronavirus]].<ref>{{cite journal | vauthors = Cavanagh D | title = Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus | journal = Avian Pathology | volume = 32 | issue = 6 | pages = 567\u201382 | date = December 2003 | pmid = 14676007 | doi = 10.1080/03079450310001621198 | doi-access = free }}</ref>\n\nPrevious projects to develop vaccines for viruses in the family ''[[Coronaviridae]]'' that affect humans have been aimed at [[severe acute respiratory syndrome coronavirus]] (SARS) and [[Middle East respiratory syndrome]] (MERS). Vaccines against SARS<ref>{{cite journal | vauthors = Gao W, Tamin A, Soloff A, D'Aiuto L, Nwanegbo E, Robbins PD, Bellini WJ, Barratt-Boyes S, Gambotto A | display-authors = 6 | title = Effects of a SARS-associated coronavirus vaccine in monkeys | journal = Lancet | volume = 362 | issue = 9399 | pages = 1895\u20136 | date = December 2003 | pmid = 14667748 | pmc = 7112457 | doi = 10.1016/S0140-6736(03)14962-8 }}</ref> and MERS<ref>{{cite journal | vauthors = Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A | display-authors = 6 | title = Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice | journal = Vaccine | volume = 32 | issue = 45 | pages = 5975\u201382 | date = October 2014 | pmid = 25192975 | pmc = 7115510 | doi = 10.1016/j.vaccine.2014.08.058 }}</ref> have been tested in non-human [[Model organism|animal models]]. As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.<ref name=\"JiangFutureVirology\">{{cite journal | vauthors = Jiang S, Lu L, Du L | title = Development of SARS vaccines and therapeutics is still needed | journal = Future Virology | volume = 8 | issue = 1 | pages = 1\u20132 | date = January 2013 | pmid = 32201503 | pmc = 7079997 | doi = 10.2217/fvl.12.126 }}</ref><ref>{{cite web|url=https://www.nhs.uk/conditions/sars/|title=SARS (severe acute respiratory syndrome)|date=5 March 2020|publisher=[[National Health Service]]|url-status=live|archive-url=https://web.archive.org/web/20200309174230/https://www.nhs.uk/conditions/sars/|archive-date=9 March 2020|access-date=31 January 2020}}</ref> According to [[Academic journal|research paper]]s published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and [[List of national public health agencies|public health agencies]] around the world.<ref name=\"PMID 15655773\">{{cite journal | vauthors = Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM | display-authors = 6 | title = Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice | journal = The Journal of Infectious Diseases | volume = 191 | issue = 4 | pages = 507\u201314 | date = February 2005 | pmid = 15655773 | pmc = 7110081 | doi = 10.1086/427242 }}</ref><ref name=\"PMID 15885812\">{{cite journal | vauthors = Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ | display-authors = 6 | title = Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins | journal = Journal of Virological Methods | volume = 128 | issue = 1\u20132 | pages = 21\u20138 | date = September 2005 | pmid = 15885812 | pmc = 7112802 | doi = 10.1016/j.jviromet.2005.03.021 }}</ref><ref name=\"PMID 16453264\">{{cite journal | vauthors = Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM | display-authors = 6 | title = Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters | journal = The Journal of Infectious Diseases | volume = 193 | issue = 5 | pages = 685\u201392 | date = March 2006 | pmid = 16453264 | pmc = 7109703 | doi = 10.1086/500143 }}</ref>\n\nThere is also no proven vaccine against MERS.<ref>{{cite journal |last1=Shehata |first1=Mahmoud M. |last2=Gomaa |first2=Mokhtar R. |last3=Ali |first3=Mohamed A. |last4=Kayali |first4=Ghazi |title=Middle East respiratory syndrome coronavirus: a comprehensive review |journal=Frontiers of Medicine |date=20 January 2016 |volume=10 |issue=2 |pages=120\u2013136 |doi=10.1007/s11684-016-0430-6 |pmid=26791756 |pmc=7089261 }}</ref> When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.<ref name=\"JiangFutureVirology\" /><ref name=\"Butler3oct2013\">{{cite journal | vauthors = Butler D | title = SARS veterans tackle coronavirus | journal = Nature | volume = 490 | issue = 7418 | pages = 20 | date = October 2012 | pmid = 23038444 | doi = 10.1038/490020a | bibcode = 2012Natur.490...20B | doi-access = free }}</ref> As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans,<ref>{{cite journal | vauthors = Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN | display-authors = 6 | title = Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial | journal = The Lancet. Infectious Diseases | volume = 19 | issue = 9 | pages = 1013\u20131022 | date = September 2019 | pmid = 31351922 | doi = 10.1016/S1473-3099(19)30266-X | doi-access = free }}</ref> and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS,  BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).<ref>{{cite journal | vauthors = Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS | title = Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus | journal = Frontiers in Microbiology | volume = 10 | pages = 1781 | year = 2019 | pmid = 31428074 | pmc = 6688523 | doi = 10.3389/fmicb.2019.01781 }}</ref>\n\n==2020 projects==\n[[COVID-19]] was identified in December 2019.<ref name=\"Fauci\">{{cite journal | vauthors = Fauci AS, Lane HC, Redfield RR | title = Covid-19 - Navigating the Uncharted | journal = The New England Journal of Medicine | volume = 382 | issue = 13 | pages = 1268\u20131269 | date = March 2020 | pmid = 32109011 | doi = 10.1056/nejme2002387 | pmc = 7121221 }}</ref> A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.<ref name=Fauci/><ref name=\"Gates\">{{cite journal | vauthors = Gates B | title = Responding to Covid-19 - A Once-in-a-Century Pandemic? | journal = The New England Journal of Medicine | date = February 2020 | pmid = 32109012 | doi = 10.1056/nejmp2003762 | doi-access = free }}</ref> Many organizations are using published genomes to develop possible [[vaccine]]s against SARS-CoV-2.<ref name=Fauci/><ref name=\"Reut_NIH_Moderna_3months\">{{cite news | last1= Steenhuysen | first1= Julie | last2= Kelland | first2= Kate | name-list-format = vanc | title= With Wuhan virus genetic code in hand, scientists begin work on a vaccine | date= 24 January 2020 | agency= [[Reuters]] | url= https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |access-date=25 January 2020 |archive-url= https://web.archive.org/web/20200125203723/https://www.reuters.com/article/us-china-health-vaccines-idUSKBN1ZN2J8 |archive-date= 25 January 2020 |url-status=live }}</ref><ref name=\"clinicaltrialsarena\">{{cite web| first = Praveen | last = Duddu | name-list-format = vanc |url=https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/|title=Coronavirus outbreak: Vaccines/drugs in the pipeline for Covid-19|publisher=Clinical Trials Arena|date=19 February 2020|access-date=19 February 2020}}</ref><ref name=\"lee\">{{cite news|last=Lee|first=Jaimy| name-list-format = vanc |url=https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06|title=These nine companies are working on coronavirus treatments or vaccines \u2014 here's where things stand|date=1 April 2020|work=[[MarketWatch]]|access-date=2 April 2020|url-status=live}}</ref> In the United States, the [[Food and Drug Administration]] announced its intent \"to use all of the regulatory flexibility granted to it by Congress to ensure the most efficient and timely development of vaccines to fight COVID-19.\"<ref>{{cite press release|url=https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments|title=Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments|publisher=U.S. [[Food and Drug Administration]] (FDA) |date=19 March 2020|access-date=7 April 2020}}</ref>\n\nSome 79 companies and academic institutions are involved in vaccine development,<ref name=milken/><ref name=thanh/> with three of them receiving support from CEPI, including projects by the [[biotechnology]] companies [[Moderna]],<ref name=\"Ziady\">{{Cite news|last=Ziady|first=Hanna| name-list-format = vanc |url=https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html|title=Biotech company Moderna says its coronavirus vaccine is ready for first tests|date=26 February 2020|access-date=2 March 2020|url-status=live|archive-url=https://web.archive.org/web/20200228083910/https://www.cnn.com/2020/02/25/business/moderna-coronavirus-vaccine/index.html|archive-date=28 February 2020|publisher=[[CNN]]}}</ref> and [[Inovio Pharmaceuticals]], and the [[University of Queensland]].<ref name=\"Guardian_CEPI_16weeks\" /> Five hundred clinical studies worldwide, across all stages of development on vaccine and therapeutic candidates for COVID-19, are registered with the World Health Organization Clinical Trial Registry, as of March 2020.<ref name=\"cheng\">{{cite journal |last1=Cheng |first1=Matthew P. |last2=Lee |first2=Todd C. Lee |last3=Tan |first3=Darrell H.S. |last4=Murthy |first4=Srinivas |title=Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic |journal=Canadian Medical Association Journal |date=26 March 2020 |pages=cmaj.200438 |doi=10.1503/cmaj.200438 |doi-access=free }}</ref>\n\nIn early March 2020, CEPI announced a US$2 billion funding goal in a global partnership between public, private, philanthropic, and civil society organisations to accelerate development of COVID-19 vaccines, with commitments to date by the governments of Denmark, Finland, Germany, Norway, and the UK.<ref name=cepi-fund/> Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.<ref name=thanh/>\n\n===Technology platforms===\nIn April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.<ref name=thanh/> Major platform targets advanced into Phase I safety studies include:\n*[[nucleic acid]] ([[DNA]] and [[RNA]]) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)\n*[[viral vector]] (Phase I developer and vaccine candidate: CanSino Biologics, [[adenovirus]] type 5 vector)\n*virus-like particle involved in [[DNA replication]] (Phase I developer and vaccine candidate: Shenzhen Geno-Immune Medical Institute, LV-SMENP)\n\nAccording to CEPI, the platforms based on DNA or [[messenger RNA]] offer considerable promise to alter COVID-19 [[antigen]] functions for strong immune responses, and can be rapidly assessed, refined for long-term stability, and prepared for large-scale production capacity.<ref name=thanh/> Other platforms being developed in 2020 focus on [[peptide]]s, [[recombinant protein]]s, live [[attenuated virus]]es, and [[Virus_processing#Viral_inactivation|inactivated viruses]].<ref name=thanh/>\n\nIn general, the vaccine technologies being developed for COVID-19 are not like vaccines already in use to prevent influenza, but rather are using \"next-generation\" strategies for precision on the COVID-19 infection mechanisms, while hastening development for eventually preventing infection with a new vaccine.<ref name=thanh/> Vaccine platforms in development are also designed to address mechanisms for infection susceptibility to COVID-19 in specific population subgroups, such as the elderly, children, pregnant women, or people with existing weakened [[immune system]]s.<ref name=thanh/>\n\nCEPI classifies development stages for vaccines as either \"exploratory\" (planning and designing a candidate, with no evaluation [[in vivo]] yet), \"preclinical\" (in vivo evaluation with preparation for manufacturing a compound to test in humans), or [[Phases of clinical research#Phase_I|initiation of Phase I safety studies in healthy people]].<ref name=thanh/>\n\n==Vaccine candidates==\nAs reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute<ref name=milken/>), and 37 others announced, but with little public information available (presumed to be in planning or being designed).<ref name=thanh/> Of the 79 confirmed active projects,<ref name=milken/> 74 are either in \"exploratory\" or \"preclinical\" development, according to the early-April CEPI report.<ref name=thanh/>\n\nIn April after the CEPI report was published, Phase I-II [[Randomized controlled trial|randomized, interventional]] trials for [[Effective dose (pharmacology)|dosing]] and assessment for [[side effect]]s began in [[Wuhan]], China on the candidate vaccine, Ad5-nCoV (CanSino Biologics, table),<ref name=liu/> and in England on the candidate, ChAdOx1 nCoV-19.<ref name=tsn-oxford/> Only five other trials on vaccine candidates are in Phase I human testing, as of mid-April.<ref name=thanh/>\n\nPhase I trials test primarily for safety and preliminary dosing in a few dozen healthy subjects, while Phase II trials, following success in Phase I, evaluate [[immunogenicity]], dose levels (efficacy based on [[biomarker]]s) and adverse effects of the candidate vaccine, typically in hundreds of people.<ref name=\"Vaccines.gov\">{{cite web |title=Vaccine Safety - Vaccines |url=https://www.vaccines.gov/basics/safety |website=www.vaccines.gov |publisher=US Department of Health & Human Services |accessdate=13 April 2020}}</ref><ref name=\"fda-ddp\">{{cite web |title=The drug development process |url=https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process |publisher=US Food and Drug Administration |access-date=12 April 2020 |date=4 January 2018}}</ref> A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.<ref name=fda-ddp/> Phase III trials typically involve more participants, and test the vaccine's effectiveness at preventing the disease as well as adverse effects, with a control group.<ref name=fda-ddp/><ref name=Vaccines.gov/>\n\n===Clinical trials===\n\n{| class=\"wikitable\"\n|-\n! colspan=\"6\" style=\"background-color: #CCEEEE;\" | COVID-19: candidate vaccines in Phase I-II trials\n|-\n! Vaccine candidate \n(developer/sponsor)\n! Technology\n! Phase of trial \n(participants)\n! Location\n! Duration\n! References \nand notes\n|-\n| '''Ad5-nCoV'''\n(CanSino Biologics)\n| recombinant adenovirus type 5 vector\n| Phase II interventional trial for dosing and side effects (500)\n| Wuhan, China\n| March 2020 to December 2020\n| <ref name=liu/><ref name=\"Phase II Ad5-nCov\">{{ClinicalTrialsGov|NCT04341389|A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)}}</ref>\n|-\n| '''Ad5-nCoV'''\n(CanSino Biologics)\n| recombinant adenovirus type 5 vector\n| Phase I (108)\n| Wuhan, China\n| March 2020 to December 2020\n| <ref name=thanh/><ref name=\"CTgov Ad5-nCoV\">{{ClinicalTrialsGov|NCT04313127|A Phase I Clinical Trial in 18-60 Adults}}</ref> <small>continuing through 2020 during Phase II start<ref name=liu/>\n|-\n| '''ChAdOx1 nCoV-19'''\n([[University of Oxford]])\n| adenovirus vector\n| Phase I-II, randomized, placebo-controlled, multiple sites (510)\n| England\n| April 2020 to May 2021\n| <ref name=tsn-oxford/><ref name=\"04324606-oxford\">{{ClinicalTrialsGov|NCT04324606|A Study of a Candidate COVID-19 Vaccine (COV001)}}</ref>\n|-\n| '''mRNA-1273'''\n([[Moderna]], US [[National Institute of Allergy and Infectious Diseases]])\n| [[lipid]] [[nanoparticle]] dispersion containing messenger RNA\n| Phase I (45)\n| United States\n| March 2020 to Spring-Summer 2021\n| <ref name=thanh/><ref name=\"NIH-director-16-March\">{{cite web |title=NIH clinical trial of investigational vaccine for COVID-19 begins |url=https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins |publisher=US National Institutes of Health |access-date=17 March 2020 |language=EN |date=16 March 2020}}</ref><ref name=\"mod-04283461\">{{ClinicalTrialsGov|NCT04283461|Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection}}</ref>\n|-\n| '''Covid-19/aAPC'''\n(Shenzhen Geno-Immune Medical Institute)\n| [[Lentiviral vector in gene therapy|lentiviral vector]], pathogen-specific artificial antigen presenting [[dendritic cell]]s \n| Phase I (100)\n| [[Shenzhen]], China\n| March 2020 to 2023\n| <ref name=thanh/><ref name=\"shenz-04299724\">{{ClinicalTrialsGov|NCT04299724|Safety and Immunity of Covid-19 aAPC Vaccine}}</ref>\n|-\n| '''LV-SMENP-DC'''\n(Shenzhen Geno-Immune Medical Institute) \n| lentiviral minigene vaccine, dendritic cells modified with lentiviral vector\n| Phase I (100)\n| Shenzhen, China\n| March 2020 to 2023\n| <ref name=thanh/><ref name=\"shenz-04276896\">{{ClinicalTrialsGov|NCT04276896|Immunity and Safety of Covid-19 Synthetic Minigene Vaccine}}</ref>\n|-\n| '''INO-4800'''\n([[Inovio Pharmaceuticals]], CEPI)\n| DNA [[plasmid]] delivered by [[electroporation]]\n| Phase I (40)\n| United States\n| April 2020 to November 2020\n| <ref name=thanh/><ref name=\"Inov-04336410\">{{ClinicalTrialsGov|NCT04336410|Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers}}</ref>\n|-\n|}\n===Preclinical research===\n{{Prose|section|date=April 2020}}\n\nOf 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in \"preclinical\" research).<ref name=thanh/><ref name=milken/>\n\n*Around 24 January 2020 in Australia, the [[University of Queensland]] announced that it is investigating the potential of a [[molecular clamp]] vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.<ref name=\"Guardian_CEPI_16weeks\">{{cite news|last1=Devlin|first1=Hannah| name-list-format = vanc |url=https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine|title=Lessons from SARS outbreak help in race for coronavirus vaccine|date=24 January 2020|newspaper=[[The Guardian]]|access-date=25 January 2020|url-status=live|archive-url=https://web.archive.org/web/20200125203322/https://www.theguardian.com/science/2020/jan/24/lessons-from-sars-outbreak-help-in-race-for-coronavirus-vaccine|archive-date=25 January 2020}}</ref>\n*Around 24 January 2020, the [[Vaccine and Infectious Disease Organization|International Vaccine Centre]] (VIDO-InterVac) at the [[University of Saskatchewan]] announced the commencement of work on a vaccine, aiming to start human testing in 2021.<ref name=\"CBC_Saskatch_6_8_weeks_nonhuman\">{{cite news|url=https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118|title=Saskatchewan lab joins global effort to develop coronavirus vaccine|date=24 January 2020|access-date=25 January 2020|url-status=live|archive-url=http://archive.today/jYfcU|archive-date=25 January 2020|publisher=[[CBC News]]|agency=[[The Canadian Press]]}}</ref>\n* Vaccine development projects were announced at the [[Chinese Center for Disease Control and Prevention]],<ref>{{cite news|last=Jeong-ho|first=Lee |last2=Zheng|first2=William|last3=Zhou|first3=Laura | name-list-format = vanc |url= https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |title=Chinese scientists race to develop vaccine as coronavirus death toll jumps|date=26 January 2020|work=[[South China Morning Post]]|access-date=28 January 2020 |url-status=live |archive-url= https://web.archive.org/web/20200126073453/https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |archive-date=26 January 2020 }}</ref> and the [[University of Hong Kong]].<ref name=\"HKvaccine\">{{cite news|last1=Cheung|first1=Elizabeth|url=https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have|title=Hong Kong researchers have developed coronavirus vaccine, expert reveals|date=28 January 2020|work=[[South China Morning Post]]|access-date=28 January 2020|url-status=live|archive-url=https://web.archive.org/web/20200128154002/https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have|archive-date=28 January 2020}}</ref>\n* Around 29 January 2020, [[Janssen Pharmaceutical Companies]], led by [[Hanneke Schuitemaker]], announced that it had begun work on developing a vaccine.<ref>{{Cite news|last=Mishra|first=Manas | name-list-format = vanc |url=https://www.reuters.com/article/us-china-health-johnson-johnson-idUSKBN1ZS1VW|title=Johnson & Johnson working on vaccine for deadly coronavirus|date=29 January 2020|access-date=19 February 2020|url-status=live|archive-url=https://web.archive.org/web/20200129231718/https://www.reuters.com/article/us-china-health-johnson-johnson-idUSKBN1ZS1VW|archive-date=29 January 2020|agency=[[Reuters]]|editor-last=Orr|editor-first=Bernard|editor-last2=Kuber|editor-first2=Shailesh}}</ref> Janssen is co-developing an oral vaccine with its biotechnology partner, [[Vaxart]].<ref name=\"nas\">{{cite web |title=Vaxart (VXRT) - A long shot or perfect shot? |url=https://www.nasdaq.com/articles/vaxart-vxrt-a-long-shot-or-perfect-shot-2020-02-25 |publisher=NASDAQ, RTTNews.com |access-date=1 March 2020 |date=25 February 2020}}</ref> On 18 March 2020, [[Emergent BioSolutions]] announced a manufacturing partnership with Vaxart to develop the vaccine.<ref>{{cite news|first=Sara|last=Gilgore| name-list-format = vanc |url=https://www.bizjournals.com/washington/news/2020/03/18/emergent-biosolutions-dives-into-another.html|title=Emergent BioSolutions dives into another coronavirus vaccine effort|work=Washington Business Journal|date=18 March 2020|access-date=18 March 2020}}</ref>\n*On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of an vaccine-design with a similar technology like the one used for cancer neoantigen vaccination therapy\" against COVID-19.<ref>{{Cite journal|last=Bojin|first=Florina|last2=Gavriliuc|first2=Oana|last3=Margineanu|first3=Michael-Bogdan|last4=Paunescu|first4=Virgil| name-list-format = vanc |date=2020-02-08|title=Design of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV)|url=https://www.preprints.org/manuscript/202002.0102/v1|language=en}}</ref> On 25 March the head of the research institute announced that they finalized the synthesis of the vaccine and that they were beginning the tests.<ref>{{Cite web|url=http://www.romania-actualitati.ro/vaccin-impotriva-noului-coronavirus-in-teste-la-oncogen-timisoara-136664|title=\"Vaccin \u00eempotriva noului coronavirus\", \u00een teste la OncoGen Timi\u0219oara - Rom\u00e2nia - Radio Rom\u00e2nia Actualit\u0103\u0163i Online|website=www.romania-actualitati.ro|access-date=2020-03-28}}</ref>\n* On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology announces they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19. They wanted to produce a vaccine candidate that could be tested in humans \"within 90 days.\"<ref>{{cite press release|url=https://www.globenewswire.com/news-release/2020/02/27/1992098/0/en/Generex-Provides-Coronavirus-Update-Generex-Receives-Contract-from-Chinese-Partners-to-Develop-a-COVID-19-Vaccine-Using-Ii-Key-Peptide-Vaccines.html|title=Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines|date=2020-02-27|access-date=2020-03-25|publisher=Generex}}</ref>\n*[[Washington University in St. Louis]] announced its projects to develop a vaccine on 5 March 2020.<ref>{{cite news |last1=Chen |first1=Eli |title=Wash U Scientists Are Developing A Coronavirus Vaccine |url=https://news.stlpublicradio.org/post/wash-u-scientists-are-developing-coronavirus-vaccine |work=St. Louis Public Radio |date=March 5, 2020 }}</ref>\n* On 5 March 2020, the [[United States Army Medical Research and Materiel Command]] at [[Fort Detrick]] and the [[Walter Reed Army Institute of Research]] in [[Silver Spring, Maryland|Silver Spring]], both in western Maryland, announced they were working on a vaccine.<ref>{{cite web |title=Defense Department Press Briefing Investigating and Developing Vaccine Candidates Against COVID-19 (Transcript) |url=https://www.defense.gov/Newsroom/Transcripts/Transcript/Article/2104736/defense-department-press-briefing-investigating-and-developing-vaccine-candidat/ |publisher=United States Department of Defense |location=Arlington, VA |date=5 March 2020 |access-date=19 March 2020}}</ref>\n* Emergent Biosolutions announced that it had teamed with [[Novavax]] Inc. in the development and manufacture of a vaccine. The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.<ref>{{cite news |last1=Gilgore |first1=Sara | name-list-format = vanc |title=Novavax's coronavirus vaccine program is getting some help from Emergent BioSolutions |url=https://www.bizjournals.com/washington/news/2020/03/10/novavax-s-coronavirus-vaccine-program-is-getting.html |work=Washington Business Journal |publisher=American City Business Journals |date=10 March 2020 |location=Charlotte, NC}}</ref>\n* On 12 March 2020, India's Health Ministry announced they are working with 11 isolates and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.<ref>{{cite news |title=Will take one-and-a-half to two years for India to develop vaccine for COVID-19: Health Ministry |url=https://economictimes.indiatimes.com/news/politics-and-nation/will-take-one-and-a-half-to-two-years-for-india-to-develop-vaccine-for-covid-19-health-ministry/articleshow/74597044.cms |work=Economic Times|date=12 March 2020 |access-date=12 March 2020}}</ref>\n* On 12 March 2020, Medicago, a biotechnology company in [[Quebec City]], [[Quebec]], reported development of a coronavirus [[virus-like particle]] under partial funding from the [[Canadian Institutes for Health Research]].<ref name=\"can-funding\">{{cite web |title=Government of Canada funds 49 additional COVID-19 research projects \u2013 Details of the funded projects |url=https://www.canada.ca/en/institutes-health-research/news/2020/03/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html |publisher=Government of Canada |access-date=23 March 2020 |date=23 March 2020}}</ref><ref name=\"abedi\">{{cite news | first = Maham | last = Abedi | name-list-format = vanc |title=Canada to spend $192M on developing COVID-19 vaccine |url=https://globalnews.ca/news/6717883/coronavirus-canada-vaccine-spending/ |access-date=24 March 2020 |work=Global News |date=23 March 2020}}</ref><ref name=\"bw3-12\">{{cite news|url=https://www.businesswire.com/news/home/20200312005345/en/|title=Medicago announces production of a viable vaccine candidate for COVID-19|date=2020-03-12|access-date=2020-03-24|work=Business Wire}}</ref> The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.<ref name=abedi/><ref name=bw3-12/>\n* On 16 March 2020, the European Commission offered an [[Euro sign|\u20ac]]80 million investment in [[CureVac]], a German biotechnology company, to develop a [[messenger RNA|mRNA]] vaccine.<ref name=\"curevac\">{{cite web |title=Coronavirus: Commission offers financing to innovative vaccines company CureVac |url=https://ec.europa.eu/commission/presscorner/detail/en/ip_20_474 |publisher=European Commission |access-date=19 March 2020 |date=16 March 2020}}</ref> Earlier that week, ''[[The Guardian]]'' reported that the US President [[Donald Trump]] had offered CureVac \"'large sums of money' for exclusive access to a Covid-19 vaccine\", against which the [[Cabinet of Germany|German government]] protested.<ref>{{cite web|url=https://www.theguardian.com/us-news/2020/mar/15/trump-offers-large-sums-for-exclusive-access-to-coronavirus-vaccine|title=Trump 'offers large sums' for exclusive access to coronavirus vaccine|first=Philip|last=Oltermann| name-list-format = vanc |newspaper=[[The Guardian]]|date=15 March 2020}}</ref>\n* On 17 March 2020, American pharmaceutical company [[Pfizer]] announced a partnership with German company [[:de:BioNTech|BioNTech]] to jointly develop a mRNA-based vaccine.<ref name=\"techcrunch\">{{Cite news |url=https://techcrunch.com/2020/03/17/pfizer-and-biontech-announce-joint-development-of-a-potential-covid-19-vaccine/ |title=Pfizer and BioNTech announce joint development of a potential COVID-19 vaccine |date=18 March 2020 |work=TechCrunch |access-date=18 March 2020}}</ref> mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.<ref>{{Cite web|url=http://www.shelstonip.com/news/covid-19-mrna-vaccines-a-promising-approach-to-vaccine-development/|title=COVID-19: mRNA vaccines \u2013 a promising approach to vaccine development|date=2020-03-23|website=Shelston IP Australia \u2013 Intellectual Property & Patent Services {{!}} IP Attorneys & IP Lawyers|language=en-US|access-date=2020-03-23}}</ref>\n* In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.<ref>{{cite press release |author=<!--Staff writer(s); no by-line.--> |title=Takis, a biotech company in Castel Romano, Rome, announced that it is ready to test its COVID-19 vaccine on pre-clinical models. |url=http://www.takisbiotech.it/images/doc/Covid-19_vaccine_on_pre-clinical_models_eng.pdf |location=Rome |publisher=Takis Biotech |agency= |date=2020-03-17 |access-date=2020-03-24}}</ref>\n* In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the [[Institut Pasteur]], Themis Bioscience ([[Vienna]], [[Austria]]), and the [[University of Pittsburgh]], bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.<ref name=\"cepi3-19\">{{cite web |title=CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine |url=https://cepi.net/news_cepi/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine/ |publisher=Coalition for Epidemic Preparedness Innovations |access-date=23 March 2020 |date=19 March 2020}}</ref> CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the [[University of Hong Kong]], the University of Oxford, and the University of Queensland.<ref name=cepi3-19/>\n* On 20 March 2020, Russian health officials announced that scientists have began animal testing of six different vaccine candidates.<ref>{{cite news |url=https://www.usnews.com/news/world/articles/2020-03-20/russia-starts-testing-coronavirus-vaccine-prototypes-on-animals |title=Russia starts testing coronavirus vaccine prototypes on animals| first = Andrew | last = Osborn | name-list-format = vanc |date=20 March 2020 |work=U.S. News & World Report|agency=Thomson Reuters |access-date=2020-03-21}}</ref>\n* [[Imperial College London]] researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19. The vaccine candidate was developed within 14 days of receiving the sequence from China.<ref>{{cite press release |first=Joanna|last=Wilson | name-list-format = vanc |title=In pictures: the Imperial lab developing a COVID-19 vaccine |url= https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid-19-vaccine/|location=London |publisher=Imperial College London |agency= |date=2020-03-20 |access-date=2020-03-24}}</ref>\n*In late March, the [[Government of Canada|Canadian government]] announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.<ref name=can-funding/><ref name=abedi/><ref name=\"CBC_Saskatch_6_8_weeks_nonhuman\"/><ref name=bw3-12/> Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national \"vaccine bank\" of several new vaccines that could be used if another coronavirus outbreak occurs.<ref name=\"abedi\" />\n*On 2 April 2020, researchers at the [[University of Pittsburgh School of Medicine]] reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that \"MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization.\"<ref name=\"TRIB-2020402\">{{cite news |last=Martines |first=Jamie | name-list-format = vanc |title=Pittsburgh scientists develop possible coronavirus vaccine, hope FDA can fast-track it |url=https://triblive.com/local/pittsburgh-allegheny/pittsburgh-scientists-say-coronavirus-vaccine-could-be-fast-tracked-after-key-animal-testing/ |date=2 April 2020 |work=[[Pittsburgh Tribune-Review]] |access-date=2 April 2020 }}</ref><ref name=\"EBM-20200402\">{{cite journal |last1=Kim |first1=Eun |last2=Erdos |first2=Geza |last3=Huang |first3=Shaohua |last4=Kenniston |first4=Thomas W. |last5=Balmert |first5=Stephen C. |last6=Carey |first6=Cara Donahue |last7=Raj |first7=V. Stalin |last8=Epperly |first8=Michael W. |last9=Klimstra |first9=William B. |last10=Haagmans |first10=Bart L. |last11=Korkmaz |first11=Emrullah |last12=Falo |first12=Louis D. |last13=Gambotto |first13=Andrea |title=Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development |journal=EBioMedicine |date=April 2020 |pages=102743 |doi=10.1016/j.ebiom.2020.102743 |pmid=32249203 |pmc=7128973 |lay-url=https://www.sciencedaily.com/releases/2020/04/200402144508.htm |lay-source=ScienceDaily |lay-date=April 2, 2020 }}</ref>\n\nIn March 2020, the US government, industry, and three universities pooled resources to access [[supercomputer]]s from [[IBM]], combined with [[cloud computing]] resources from [[Hewlett Packard Enterprise]], [[Amazon (company)|Amazon]], [[Microsoft]], and [[Google]].<ref name=\"cnet\">{{Cite web|url=https://www.cnet.com/news/sixteen-supercomputers-tackle-coronavirus-cures-in-us/|title=Sixteen supercomputers tackle coronavirus cures in US|last=Shankland|first=Stephen| name-list-format = vanc |website=CNET|language=en|access-date=2020-03-23}}</ref><ref name=\"covidhpc\">{{cite web|url=https://covid19-hpc.mybluemix.net |title=Homepage of The COVID-19 High Performance Computing Consortium | access-date=2020-03-28}}</ref> The ''COVID-19 High Performance Computing Consortium'' is being used to [[Forecasting|forecast]] disease spread, [[Data modeling|model]] possible vaccines, and [[High-throughput screening|screen]] thousands of chemical compounds to design a COVID-19 vaccine or therapy.<ref name=cnet/><ref name=covidhpc/>\n\nAn additional consortium of Microsoft, six universities (including one in the first consortium), and the [[National Center for Supercomputer Applications]], working under the auspices of C3.ai, a company founded by billionaire software developer [[Thomas Siebel]], are currently pooling their supercomputer resources for the same uses alongside developing medical protocols and strengthening public health strategies around the world, as well as awarding large grants to researchers who propose to use AI to carry out similar tasks by May.<ref>{{cite web|url=https://c3.ai/c3-ai-microsoft-and-leading-universities-launch-c3-ai-digital-transformation-institute/ |title=C3.ai, Microsoft, and Leading Universities Launch C3.ai Digital Transformation Institute |date=2020-03-26 |access-date=2020-03-28}}</ref><ref>{{cite news|last=Broad |first=William | name-list-format = vanc |url=https://www.nytimes.com/2020/03/26/science/ai-versus-the-coronavirus.html |title=A.I. Versus the Coronavirus |website=The New York Times |date=2020-03-26 |access-date=2020-03-28}}</ref>\n\n===Non-specific vaccine===\n\nSome vaccines have [[heterologous effects]], also called non-specific effects. That means they can have benefits beyond the disease they prevent.<ref name=\"Kleinnijenhuis 2015\">{{cite journal |last1=Kleinnijenhuis |first1=J |last2=van Crevel |first2=R |last3=Netea |first3=MG |title=Trained immunity: consequences for the heterologous effects of BCG vaccination. |journal=Transactions of the Royal Society of Tropical Medicine and Hygiene |date=January 2015 |volume=109 |issue=1 |pages=29-35 |doi=10.1093/trstmh/tru168 |pmid=25573107}}</ref> The anti-tuberculosis vaccine, [[BCG vaccine]], is an example that is being tested to determine if it has a protective effect against COVID-19, pursuant to assertions that COVID-19 mortality was lower in countries having routine BCG vaccine administration.<ref name=\"deVrieze-April\">{{cite journal |last1=de Vrieze |first1=Jop |title=Can a century-old TB vaccine steel the immune system against the new coronavirus? |journal=Science |date=March 23, 2020 |doi=10.1126/science.abb8297 |url=https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus |accessdate=11 April 2020}}</ref>\n\nIn March 2020, a randomized trial of BCG vaccine to reduce COVID-19 illness began in the Netherlands, seeking to recruit 1,000 healthcare workers.<ref name=\"BCG-EudraCT\">{{cite web |title=EudraCT 2020-000919-69 |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL |website=EU Clinical Trials Register |publisher=European Union |accessdate=11 April 2020}}</ref> A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.<ref name=\"MCRI-BCG-trial\">{{cite web |title=Murdoch Children\u2019s Research Institute to trial preventative vaccine for COVID-19 healthcare workers |url=https://www.mcri.edu.au/news/murdoch-children%E2%80%99s-research-institute-trial-preventative-vaccine-covid-19-healthcare-workers |website=www.mcri.edu.au |publisher=Murdoch Children's Research Institute |accessdate=11 April 2020 |language=en}}</ref><ref name=\"CT.gov BCG Australia\">{{cite web |title=BCG Vaccination to Protect Healthcare Workers Against COVID-19 - Full Text View - ClinicalTrials.gov |url=https://clinicaltrials.gov/ct2/show/NCT04327206 |website=clinicaltrials.gov |publisher=US National Library of Medicine, National Institutes of Health |accessdate=11 April 2020 |language=en}}</ref>\n\n==Potential limitations==\nIt is possible vaccines in development will not be safe or effective.<ref name=\"Thorp\">{{cite journal |last1=Thorp |first1=H. Holden |title=Underpromise, overdeliver |journal=Science |date=27 March 2020 |volume=367 |issue=6485 |pages=1405 |doi=10.1126/science.abb8492 |pmid=32205459 |doi-access=free }}</ref> One study found that between 2006 and 2015, the success rate of obtaining approval from Phase I to successful Phase III trials was 16.2% for vaccines,<ref name=\"bio\">{{cite web|url=https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf|title=Clinical Development Success Rates 2006-2015|date=June 2016|publisher=BIO Industry Analysis}}</ref> and CEPI indicates a potential success rate of only 10% for vaccine candidates in 2020 development.<ref name=thanh/>\n\nThe rapid development and urgency of producing a vaccine for the COVID-19 pandemic may increase the risks and failure rate of delivering a safe, effective vaccine.<ref name=thanh/> Early research to assess vaccine efficacy using COVID-19-specific animal models, such as [[ACE2]]-[[transgenic]] mice, other laboratory animals, and non-human primates, indicate a need for [[biosafety]]-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.<ref name=thanh/> An April 2020 CEPI report stated: \"strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions.\"<ref name=thanh/>\n\nWhile the [[flu vaccine]] is typically [[Mass production|mass-produced]] by injecting the virus into [[chicken egg]]s, this method will not work for the COVID-19 vaccine, as the SARS-CoV-2 virus cannot replicate inside eggs.<ref>{{Cite web|url=https://www.cnn.com/2020/03/27/health/chicken-egg-flu-vaccine-intl-hnk-scli/index.html|title=Millions of chickens are used to make vaccines each year. But that won't work for coronavirus|last=Yeung|first=Jessie| name-list-format = vanc |date=29 March 2020|website=CNN|url-status=live|archive-url=|archive-date=|access-date=2020-04-04}}</ref>\n\n==Misinformation==\n{{main|Misinformation related to the 2019\u201320 coronavirus pandemic}}\nSocial media posts have promoted a [[conspiracy theory]] claiming the virus behind COVID-19 was known and that a vaccine was already available. The patents cited by various [[social media]] posts reference existing patents for [[genetic sequence]]s and vaccines for other strains of coronavirus such as the [[Severe acute respiratory syndrome-related coronavirus|SARS coronavirus]].<ref>{{Cite web|url=https://www.politifact.com/factchecks/2020/jan/23/facebook-posts/there-outbreak-china-wuhan-coronavirus-there-not-v/|title=No, there is no vaccine for the Wuhan coronavirus|last=Kertscher|first=Tom| name-list-format = vanc |date=23 January 2020|website=[[PolitiFact]]|publisher=[[Poynter Institute]]|url-status=live|archive-url=https://web.archive.org/web/20200207133056/https://www.politifact.com/factchecks/2020/jan/23/facebook-posts/there-outbreak-china-wuhan-coronavirus-there-not-v/|archive-date=7 February 2020|access-date=7 February 2020}}</ref><ref name=\"20200124factcheckA\">{{Cite web|url=https://www.factcheck.org/2020/01/social-media-posts-spread-bogus-coronavirus-conspiracy-theory/|title=Social Media Posts Spread Bogus Coronavirus Conspiracy Theory|last=McDonald|first=Jessica| name-list-format = vanc |date=24 January 2020|website=[[FactCheck.org]]|publisher=[[Annenberg Public Policy Center]]|url-status=live|archive-url=https://web.archive.org/web/20200206102802/https://www.factcheck.org/2020/01/social-media-posts-spread-bogus-coronavirus-conspiracy-theory/|archive-date=6 February 2020|access-date=8 February 2020}}</ref>\n\n== See also ==\n* [[2019\u201320 coronavirus pandemic]]\n* [[Coronavirus disease 2019]]\n* [[Severe acute respiratory syndrome coronavirus 2]]\n* [[2009 flu pandemic vaccine]]\n* [[Respiratory disease]]\n* [[COVID-19 drug development]]\n* [[Phases of clinical research]]\n{{Portal bar|Coronavirus disease 2019|Medicine|Modern history|Viruses|Current events|border=no}}\n\n== References ==\n{{reflist}}\n\n== External links ==\n* {{cite web | url=https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker | title=COVID-19 Vaccine Tracker | website=Regulatory Focus }}\n\n{{2019\u201320 coronavirus pandemic}}\n{{Vaccines}}\n\n[[Category:Vaccines]]\n[[category:COVID-19|Vaccine]]\n[[Category:Medical research]]\n", "name_user": "Zefr", "label": "safe", "comment": "\u2192\u200eVaccine candidates:ce, wlinks, ref order", "url_page": "//en.wikipedia.org/wiki/COVID-19_vaccine"}
